TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment. 

TCT 2024 | Utilización de balones cubiertos de fármacos para el tratamiento de la rama lateral en técnica de stent provisional

The primary objective was to assess patency and a composite outcome of target vessel revascularization (TVR), major amputation, and procedure- or device-related death over a 12-month follow-up.

A total of 842 patients were enrolled between April 2021 and September 2022 across 25 clinics in Germany and Austria, with follow-up at one year.

Lesions averaged 84 ± 61 mm in length; 34% of them were chronic total occlusions (CTO), and 45% had grade 3 calcification per PACSS classification. Bailout stenting was required in 23% of cases.

Primary patency was assessed through Doppler ultrasound, which showed a 73.8% primary success rate (primary endpoint) for the sirolimus-coated balloon group vs 75% for the paclitaxel-coated balloon, with a difference of -1.2% (95% confidence interval [CI]: -9.7% to 7.4%, P for non-inferiority = 0.022).

Read also: TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions.

Regarding safety outcomes, there was a 2.1% difference in adverse events (95% CI: -3.2% to 7.5%, P for non-inferiority = 0.003), with no mortality events. Freedom from re-intervention was 92.9% in the sirolimus group vs 95.4% in the paclitaxel group (log rank = 0.58).

The authors concluded that, in this direct comparison, sirolimus- and paclitaxel-coated balloons showed comparable results, thus achieving non-inferiority.

Presented by Ulf Teichgräber in the Late-Breaking Trials Sessions, TCT 2024, October 27-29, Washington, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Chronic Thromboembolic Pulmonary Hypertension: Treatment Outcomes According to a Worldwide Registry

Chronic thromboembolic pulmonary hypertension (CTEPH) is a highly limiting condition that, despite its moderate incidence, significantly impacts patient prognosis and quality of life. The...

Contemporary Outcomes of Acute Limb Ischemia Endovascular Revascularization

Acute limb ischemia (ALI) is a vascular emergency with high mortality rate. It has been defined as a sudden occlusion of limb perfusion compromising...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...